###### Key messages

What is already known about this subject?
=========================================

Acute kidney injury (AKI) causes significant morbidity and mortality when it occurs after cardiac surgery. As it is due to multiple factors, so far, there has not been any major treatment strategy to prevent it from occurring.

What does this study add?
=========================

This pilot study assessed if it was feasible to use the RenalGuard system in patients undergoing cardiac surgery when the cardiopulmonary bypass machine is used. In this small series feasibility was demonstrated as well as a possible clinical benefit in reducing AKI after cardiac surgery.

How might this impact on clinical practice?
===========================================

This pilot study has led the way to set up a randomised control trial to assess the clinical benefit and safety of the use of the RenalGuard system. If clinical benefit is proven, using the RenalGuard system will improve cardiac surgery morbidity and mortality significantly by reducing AKI.

Introduction {#s1}
============

Acute kidney injury (AKI) is reported in 2%--30% of patients undergoing cardiac surgery.[@R1] This variability is due to a spectrum of definitions used to classify AKI. It is now customary to use the Risk, *Injury*, *Failure*, Loss of *kidney *function, and End-stage *kidney *disease (RIFLE),[@R2] or the Acute *Kidney Injury *Network (AKIN) consensus criteria.[@R4] The development of AKI in the postop cardiac surgery setting is associated with significant morbidity,[@R5] mortality,[@R5] prolonged intensive care unit (ICU) and inhospital stays,[@R7] increased treatment costs and poorer long-term survival and quality of life.[@R7] As yet, no satisfactory strategy has been successful in preventing AKI despite identifying patients who are at risk of developing AKI.

Previous experience {#s1a}
-------------------

Pharmacological interventions to reduce AKI have produced inconsistent results and include the use of preoperative hydration, dopamine, mannitol and dexamethasone.[@R10] Evidence for the use of furosemide alone has also been conflicting. Diuretics reduce renal oxygen consumption and high urine outputs can be achieved with intravenous furosemide during cardiac surgery.[@R11] Continuous intravenous furosemide infusion has been shown to reduce the need for postoperative haemofiltration but contrasting studies have even shown detrimental effects of using perioperative furosemide.[@R12] Importantly, forced diuresis with furosemide can lead to volume depletion if adequate fluid replacement is not achieved which may adversely impact on renal perfusion. It is therefore not yet clear whether forced diuresis with simultaneous balancing of urine output with intravenous fluid infusion (to prevent hypovolaemia) would be of benefit in reducing AKI. Forced diuresis to achieve high urine flow rate of \>150 mL/hour has shown to reduce serum creatinine levels.[@R13] However, use of high dose of diuretics (furosemide \>1 mg/kg) and associated hypovolaemia resulted in high incidence of AKI.[@R14] The RenalGuard system uses low dose of diuretics to initiate the forced diuresis and maintains intravascular volume by infusing maintenance fluids to match the urine output.

New intervention {#s1b}
----------------

The use of the RenalGuard system (RenalGuard, PLC Medical Systems, Milford, Massachusetts, USA) has been investigated at reducing AKI in patients at risk of contrast-induced nephropathy when undergoing either percutaneous coronary intervention (PCI) or transcatheter aortic valve implantation (TAVI).[@R13] These studies showed that in patients with chronic kidney disease, the RenalGuard System reduced the incidence of AKI by 60%--75% as compared with controls. The RenalGuard system uses forced diuresis with low dose (0.25--0.5 mg/kg) of furosemide along with administration of intravenous fluids matched in real time to urine output to prevent inadvertent volume depletion. It should be noted, however, that AKI in these situations is due to contrast nephropathy but in the setting of cardiopulmonary bypass (CPB), the aetiology of the AKI is likely to be multifactorial.

The RenalGuard system {#s1c}
---------------------

The various components of this system have previously been reported.[@R17] Essentially, it includes a closed-loop fluid management system, a high-volume fluid pump, a high-accuracy dual weight measuring system, motion-detection artefact reduction, a single-use intravenous set and urine collection system that interfaces with a standard Foley catheter, real-time display of urine and replacement fluid volume, timely alerts to drain the urine bag or to replace the hydration fluid bag, and safety features such as automatic air and occlusion detection. The console measures the volume of urine in the collecting set (also calculates the urine flow rate) and infuses an equal volume of hydration fluid to match the urine output. The console allows the user to set to achieve a net fluid gain or loss above matched hydration. The console also allows infusion of a bolus of fluids at the user's request.

The use of the RenalGuard system in patients undergoing cardiac surgery has not been investigated. We describe our initial first-in-man experience with this system in cardiac surgery patients and evaluate: (A) the feasibility and safety of using the device, particularly during CPB, (B) the impact of its use on electrolytes, fluid balance and haemoglobin levels and (C) its effect on kidney function in the postoperative phase.

Methods {#s2}
=======

Patient's selection for being at risk of developing AKI was based on our unit's own experience,[@R7] and previous report.[@R1] For the purpose of this pilot study, the RIFLE definition for AKI was used. Creatinine was used as the marker for AKI rather than cystatin-c or neutrophil gelatinase-associated lipocalin. Ten consecutive patients (under the care of a single surgeon---HL) who were at risk of developing AKI were selected. During that same period 41 patients underwent cardiac surgery under the care of the same surgeon. The patients were anaesthetised by the same anaesthetist (RG).

This project was reviewed and ethically agreed by the Hospital's 'Patients Safety Investigation Group (PSIG)' as an initial evaluation of the device (Reference T:PSIG/JAN2016, meeting date 15 January 2016). All patients gave written consent for the use of the device and patients were treated according to the Declaration of Helsinki 1964 (amended Edinburgh 2000).

In previous reports, when used in patients undergoing PCI or TAVI, the RenalGuard system was started around 90 min preprocedure in order to achieve a urine output rate of 300 mL/hour prior to contrast injection. It was then continued during the procedure and for 4 hours after last contrast injection.[@R16] We aimed to apply a similar protocol for our patient group but elected to continue for longer (6--12 hours on ICU) in recognition of the late renal damage seen in previous studies in cardiac surgery.[@R19] Patients were commenced on intravenous Hartmann's solution controlled by the RenalGuard system.

Furosemide (20 mg) was administered intravenously to achieve an optimal urine flow of 300 mL/hour. Controlled hydration by the RenalGuard system continued during the procedure and for 6--12 hours after the patient was transferred to the cardiac intensive care unit (CICU). Urine flow was monitored and maintained at the target value throughout and additional furosemide doses were given when urine flow fell below this target value. Real-time matched hydration was facilitated by the RenalGuard system in all patients, that is, any volume of urine produced was matched by infusion with the same volume of Hartmann's solution instantaneously.

CPB was carried out using the centrifugal pump in a non-pulsatile mode aiming for a flow of 2.4 L/min/m^2^ at mild hypothermia (34°C for coronary artery bypass grafting (CABG) and 32°C for  aortic valve replacement (AVR)). For patients undergoing CABG, the proximal anastomoses were performed with the cross-clamp still in situ (ie, a single clamp technique).

Categorical data are expressed as percentage. Continuous variables are expressed as mean (SD) or median (range) for Gaussian and skewed distributed data, respectively.

Results {#s3}
=======

The patients' characteristics are summarised in [table 1](#T1){ref-type="table"}.

###### 

The patients' preop characteristics

  Ptnum   Gender   Age, years   Diabetes   PVD   Priority   CABG   Valve   LogEuroscore
  ------- -------- ------------ ---------- ----- ---------- ------ ------- --------------
  1       Male     51           NIDDM      No    Urgent     Yes    No      0.88
  2       Female   76           Non        No    Elective   Yes    Yes     6.19
  3       Male     71           NIDDM      No    Elective   Yes    No      1.94
  4       Male     82           Non        No    Elective   Yes    Yes     10.38
  5       Male     74           Non        Yes   Urgent     Yes    No      14.1
  6       Male     66           Non        No    Urgent     Yes    No      2.11
  7       Male     63           Non        No    Elective   Yes    No      6.24
  8       Male     76           NIDDM      No    Elective   Yes    No      2.69
  9       Male     57           NIDDM      Yes   Elective   Yes    No      2.54
  10      Male     74           NIDDM      Yes   Elective   Yes    No      4.45

CABG, coronary artery bypass grafting; IDDM, Insulin dependent diabetes; NIDDM, non-insulin dependent diabetes; Ptnum, patient number; PVD, peripheral vascular disease.

For the first three patients, the RenalGuard system was initiated 1 hour prior to the patient being transferred to the anaesthetic room (around 2 hours prior to skin incision). Thereafter, for the remaining seven patients, the system was initiated in the anaesthetic room (around 1 hour prior to skin incision) after induction of anaesthesia. For the first five patients, the RenalGuard system was continued for 12 hours post-transfer to CICU while for the latter five patients the system was discontinued after 6 hours post-CICU transfer. These adjustments were made as we learnt more about the way the device functioned in patients undergoing cardiac surgery.

During this assessment period, matched diuresis with the RenalGuard system was achieved in all patients, even during CPB when reduced urine output might be anticipated. The changes in the serum creatinine and estimated Glomerular filtration rate (eGFR) between preop and postop values are shown in [table 2](#T2){ref-type="table"} and urine as well as Hartmann's replacement volumes are depicted in [table 3](#T3){ref-type="table"}.

###### 

The serum creatinine and eGFR between preop and postop values

  Ptnum   preop eGFR   Preop creatinine   Discharge eGFR   Creat D1   Creat D2   Creat D3   Max % change in Creat
  ------- ------------ ------------------ ---------------- ---------- ---------- ---------- -----------------------
  1       90           72                 90               95         72         75         31%
  2       49           97                 N/A              120        123        97         27%
  3       89           72                 90               61         82         66         14%
  4       36           170                30               143        155        172        1%
  5       44           135                40               157        142        146        16%
  6       33           180                28               186        202        213        18%
  7       27           217                24               273        279        242        29%
  8       86           72                 90               77         76         74         4%
  9       61           105                63               98         114        103        9%
  10      57           110                51               138        152        136        27%

eGFR, estimated glomerular filtration rate (Cockfroft-Gault); Creat D1, creatinine level on day 1 postop; Creat D2, creatinine level on day 2 postop; Creat D3, creatinine level on day 3 postop (serum creatinine in µmol/L (to convert to mg/dL, divide by 88.4)); Ptnum, patient number.

###### 

Urine and Hartmann's replacement volumes during RenalGuard use

  Ptnum   Furosemide bolus   Additional furosemide   Total urine (mL)   Total intravenous Hartmann's solution (mL)   Total time (hours)   Weight (kg)   BSA    Urine (ml/hour/BSA)
  ------- ------------------ ----------------------- ------------------ -------------------------------------------- -------------------- ------------- ------ ---------------------
  1       20 mg              20 mg × 5 bolus         9350               9848                                         18                   77            1.89   275
  2                          20 mg × 3 bolus         2947               3206                                         13                   80            1.75   130
  3       40 mg              20 mg bolus             7226               7478                                         18                   104           2.32   173
  4       40 mg              20 mg bolus             4539               4538                                         12                   98            2.08   182
  5       40 mg              5 mg infusion           4964               4895                                         12                   70            1.77   234
  6       20 mg              5 mg infusion           3972               3974                                         11                   76            1.92   188
  7       40 mg              5 mg infusion           2076               2076                                         11                   94            2.08   91
  8       40 mg              5 mg infusion           5358               5361                                         13                   108           2.23   185
  9       20 mg              10 mg infusion          5372               5373                                         10                   74            1.8    298
  10      40 mg              10 mg infusion          5051               5051                                         10                   71            1.85   273

BSA: body surface area; Ptnum, patient number.

The changes in electrolytes (potassium), lactate and haemoglobin levels for each patient along the various time points are illustrated in [figure 1A-C](#F1){ref-type="fig"}.

![(A) Serum potassium levels for each patient at various time intervals. (B) Serum lactate levels for each patient at various time intervals.(C) Haemoglobin levels for each patient at various time intervals. Time intervals: T1---prestart of RenalGuard system---baseline; T2---poststart of RenalGuard system/pre-cardiopulmonary bypass (CPB) start. T3---within 15 min after CPB initiation. T4---60 min postinitiation of CPB. T5---post-CPB. T6---on admission to CICU. T7---4 hours post-CICU admission. T8---8 hours post CICU admission. T9---16 hours post CICU admission.](openhrt-2017-000669f01){#F1}

Only one patient required continuous venovenous haemofiltration (CVVHF) on day 2 after developing acute right ventricular failure. The other patients did not have any significant deterioration in renal function despite one patient developing cardiac tamponade 8 hours postoperatively and one patient developing paralytic ileus. Other postoperative complications are listed in [table 4](#T4){ref-type="table"}.

###### 

Perioperative and postoperative data

  Ptnum   CPB time (mins)   ICU stay (days)   AF   Confusion   Stroke   GI comp   CVVHF   Postoperative stay (days)
  ------- ----------------- ----------------- ---- ----------- -------- --------- ------- ---------------------------
  1       109               1                 No   No          No       No        No      3
  2       93                --                No   No          No       No        Yes     --
  3       90                1                 AF   No          No       No        No      7
  4       131               1                 AF   No          No       No        No      9
  5       95                5                 No   No          No       Ileus     No      36
  6       102               1                 No   No          No       No        No      4
  7       120               2                 No   No          No       No        No      7
  8       152               3                 AF   No          Yes      Ileus     No      --
  9       76                3                 No   No          No       No        No      5
  10      97                2                 No   No          No       No        No      5

CPB time, duration of cardiopulmonary bypass; ICU, intensive care unit; AF, atrial fibrillation; GI, gastrointestinal; CVVHF, continuous venovenous haemofiltration; Ptnum, patient number.

Two patients died, one of sudden acute right ventricular failure and the other due to a stroke 1 week postoperatively. Both of these were not thought to be related to the use of the RenalGuard system.

Median CICU stay was 1.5 (1, 5) days and median inhospital stay was 6 (3, 36) days. The long duration of inhospital stay related to (A) patient '5' who developed several episodes of intermittent acute bowel obstruction on a background of previous abdominourological surgery (cystectomy for bladder cancer and formation of an ileal urostomy) and (B) patient '8' who developed a stroke a week postop requiring CICU readmission and re-intubation.

Discussion {#s4}
==========

The RenalGuard system can be used successfully and safely in patients undergoing cardiac surgery with the CPB machine.

During our experience, the device set-up was modified as compared when used in patients undergoing PCI and TAVI. The initiation of the device is feasible after induction of anaesthesia and a urine output of 200--300 mL/min is acceptable during the whole process. Lower urine outputs on the CICU might be an early indicator of reduced renal perfusion. Indeed, in two patients who developed postoperative mechanical complications (one developed severe right ventricular dysfunction and the other developed tamponade requiring surgical intervention), reduced urine flow was the first indicator of physiological compromise despite otherwise normal haemodynamic measurements at that point in time.

The urine flow decreased soon after induction of anaesthesia and returned to the desired level (200--300 mL/min) provided the mean arterial pressure was maintained at \>65 mm Hg. In hypertensive patients, this level can be as high as 75 mm Hg. After knife-to-skin and prior to initiation of CPB, similar changes were noted. Hence, this part of the procedure can be an important contributing factor to the development of AKI and is often overlooked.

When the CPB was initiated, the urine flow was dependent on the mean perfusion pressure, the flow rate as set by the CPB machine and the presence of pulsatility. The latter was more evident in the patient with chronic kidney disease (CKD) (patient 7). His urine flow was zero throughout the whole CPB run despite increasing mean arterial pressure (MAP). Interestingly despite starting with a preoperative creatinine of 217 micromol/L (eGFR 41) and having no urine output during the 120 min of the CPB run, he maintained a good urine output in the postop period. He did not develop AKI as per RIFLE criteria with his creatinine peaking at 279 micromol/L and his ICU stay was only 2 days. He did not require CVVHF.

Previous studies of furosemide in cardiac surgery (without matched hydration) have shown the ability to achieve polyuria but this has not consistently translated into renal protection.[@R20] A randomised study comparing furosemide infusion with placebo showed a threefold increase in urine outputs with furosemide without any significant reduction in 12-hour postoperative serum creatinine. However, only 25% extra intravenous fluid was used in the furosemide group which may have led to relative hypovolaemia and limited any benefits of forced diuresis.[@R20] The RenalGuard system therefore ensures that neutral fluid balance is maintained throughout despite forced diuresis and may mitigate against the risks of hypovolaemia and consequent renal damage.

Finally, should this device be proven to be beneficial to the patients in the cardiac surgery setting, then appropriate cost-analysis studies will be required to assess the cost of the device as offset to the cost of treating AKI, especially bearing in mind the cost of CVVHF and prolonged ICU stay.

This study was performed and reported as per the STROBE recommendations.[@R21]

Limitations {#s4a}
-----------

This is a small report of 10 patients assessing the feasibility and potential benefit of the RenalGuard system. It is limited by the small number in the group and the lack of a randomised comparison group. Moreover, the patients selected were those who were felt to be at risk of developing AKI. Thus the findings of this study cannot be generalised as yet until further information from a randomised control trial is available.

Conclusion {#s5}
==========

This first-in-man assessment of the RenalGuard system in patients undergoing cardiac surgery with the CPB machine has shown that this is feasible. The clinically significant benefits as well as any cost savings will need to be investigated by a randomised control trial. This has been set up (ClinicalTrials.gov: NCT02974946). Recruitment has started and the study will report in around 18 months.
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